Intervacc AB (publ) (STO:IVACC)

Market Cap	391.94M
Revenue (ttm)	18.24M
Net Income (ttm)	-71.21M
Shares Out	340.81M
EPS (ttm)	-0.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,632
Average Volume	753,378
Open	1.188
Previous Close	1.162
Day's Range	1.130 - 1.188
52-Week Range	0.729 - 3.450
Beta	0.50
RSI	58.84
Earnings Date	Aug 29, 2025

About Intervacc AB

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 15
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IVACC

Financial Performance

In 2024, Intervacc AB's revenue was 11.79 million, an increase of 46.84% compared to the previous year's 8.03 million. Losses were -75.52 million, -26.58% less than in 2023.